These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28767518)

  • 1. Bayesian Model Averaging with Change Points to Assess the Impact of Vaccination and Public Health Interventions.
    Kürüm E; Warren JL; Schuck-Paim C; Lustig R; Lewnard JA; Fuentes R; Bruhn CAW; Taylor RJ; Simonsen L; Weinberger DM
    Epidemiology; 2017 Nov; 28(6):889-897. PubMed ID: 28767518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.
    Andrade AL; Minamisava R; Policena G; Cristo EB; Domingues CM; de Cunto Brandileone MC; Almeida SC; Toscano CM; Bierrenbach AL
    Hum Vaccin Immunother; 2016; 12(2):285-92. PubMed ID: 26905679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses.
    Suarez V; Michel F; Toscano CM; Bierrenbach AL; Gonzales M; Alencar AP; Ruiz Matus C; Andrus JK; de Oliveira LH
    Vaccine; 2016 Sep; 34(39):4738-4743. PubMed ID: 27521230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
    Fitzwater SP; Chandran A; Santosham M; Johnson HL
    Pediatr Infect Dis J; 2012 May; 31(5):501-8. PubMed ID: 22327872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis.
    Andrade AL; Afonso ET; Minamisava R; Bierrenbach AL; Cristo EB; Morais-Neto OL; Policena GM; Domingues CMAS; Toscano CM
    PLoS One; 2017; 12(9):e0184204. PubMed ID: 28880953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
    Mitchell R; Trück J; Pollard AJ
    Expert Opin Biol Ther; 2013 Oct; 13(10):1451-65. PubMed ID: 23889554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of implementing the 10-valent pneumococcal conjugate vaccine on hospitalizations for pneumonia among children.
    de Melo Araujo AC; da Silva Aragão J; de Souza WV; Rodrigues LC; de Barros Miranda-Filho D
    Vaccine; 2023 Jul; 41(32):4719-4725. PubMed ID: 37353456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.
    Slotved HC; Dalby T; Hoffmann S
    Vaccine; 2016 Feb; 34(6):769-74. PubMed ID: 26772630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of pneumococcal disease prevention.
    Rodgers GL; Klugman KP
    Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil.
    Warren JL; Shioda K; Kürüm E; Schuck-Paim C; Lustig R; Taylor RJ; Simonsen L; Weinberger DM
    Clin Infect Dis; 2017 Nov; 65(11):1813-1818. PubMed ID: 29020195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Jan; 58(1):1-4. PubMed ID: 19145219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects.
    Davis SM; Deloria-Knoll M; Kassa HT; O'Brien KL
    Vaccine; 2013 Dec; 32(1):133-45. PubMed ID: 23684824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Epidemiology and Biostatistics of Pneumococcus.
    Oligbu G; Fry NK; Ladhani SN
    Methods Mol Biol; 2019; 1968():215-224. PubMed ID: 30929218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    De Wals P; Lefebvre B; Markowski F; Deceuninck G; Defay F; Douville-Fradet M; Landry M
    Vaccine; 2014 Mar; 32(13):1501-6. PubMed ID: 24486346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap?
    Kornetsky R; Greenberg D; Falup-Pecurariu O
    Antibiot Khimioter; 2016; 61(11-12):63-67. PubMed ID: 29558061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.